Exscientia, an artificial intelligence-driven pharmatech company, has chosen Milton Park for new laboratories as it expands its footprint in Oxfordshire. The move confirms continued growth for Exscientia, which recently topped the 2021 edition of The Business Magazine's Thames Valley SME Growth 100 index.
Founded in 2012, Exscientia utilises AI-led technology to discover and design medicines and treatments faster and more efficiently than through conventional methods.
Exscientia chose Milton Park as the location to expand its footprint thanks to its impressive life sciences ecosystem, strong community collaboration and long-term track record of nurturing businesses.
Exscientia’s expansion will see the firm occupy 20,151 sq ft of laboratory and office space at 155 Brook Drive, which is part of the Science Vale Enterprise Zone.
Andrew Hopkins, CEO, Exscientia, said: "We’re delighted to have chosen Milton Park for new laboratories as part of the next stage of our business growth. This new, state-of-the-art space is the ideal location for Exscientia as we bring more highly-skilled people into the business with the ability to deploy and continue to develop innovative technology to create new medicines and treatments faster and more efficiently, benefitting patients worldwide."
Tom Booker, Commercial Manager, MEPC Milton Park, said: "Providing spaces for life sciences companies at the forefront of innovation is at the heart of what we do at Milton Park, so we‘re absolutely delighted to offer a site to Exscientia as their plans for growth come to life.
"Exscientia’s pioneering use of AI technology to make the discovery of medicines more efficient is perhaps more pertinent than ever in light of Covid-19. We’re very pleased to welcome Exscientia to the Milton Park community at what is an exciting point in their evolution."
Milton Park is home to 250 businesses and innovative enterprises, making it one of Europe’s largest science and technology parks.
Exscientia is an AI-driven pharmatech company and the first company to progress AI-designed small molecules into the clinical setting. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Exscientia has offices in Oxford, Miami, Osaka and Dundee.
Pictured: Milton Park